APA

Ramirez-Ardila D. E., Helmijr J. C., Look M. P., Lurkin I., Ruigrok-Ritstier K., van Laere S., Dirix L., Sweep F. C., Span P. N., Linn S. C., Foekens J. A., Sleijfer S., Berns E. M. J. J. & Jansen M. P. H. M. (20131023). Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen. : Breast cancer research and treatment.

Chicago

Ramirez-Ardila Diana E, Helmijr Jean C, Look Maxime P, Lurkin Irene, Ruigrok-Ritstier Kirsten, van Laere Steven, Dirix Luc, Sweep Fred C, Span Paul N, Linn Sabine C, Foekens John A, Sleijfer Stefan, Berns Els M J J and Jansen Maurice P H M. 20131023. Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen. : Breast cancer research and treatment.

Harvard

Ramirez-Ardila D. E., Helmijr J. C., Look M. P., Lurkin I., Ruigrok-Ritstier K., van Laere S., Dirix L., Sweep F. C., Span P. N., Linn S. C., Foekens J. A., Sleijfer S., Berns E. M. J. J. and Jansen M. P. H. M. (20131023). Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen. : Breast cancer research and treatment.

MLA

Ramirez-Ardila Diana E, Helmijr Jean C, Look Maxime P, Lurkin Irene, Ruigrok-Ritstier Kirsten, van Laere Steven, Dirix Luc, Sweep Fred C, Span Paul N, Linn Sabine C, Foekens John A, Sleijfer Stefan, Berns Els M J J and Jansen Maurice P H M. Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen. : Breast cancer research and treatment. 20131023.